These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6419536)

  • 21. [Sodium valproate: a hyperammonemic drug. Study in the epileptic and healthy volunteer].
    Marescaux C; Warter JM; Laroye M; Rumbach L; Micheletti G; Koehl C; Imler M; Kurtz D
    J Neurol Sci; 1983 Feb; 58(2):195-209. PubMed ID: 6403673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.
    Gerstner T; Buesing D; Longin E; Bendl C; Wenzel D; Scheid B; Goetze G; Macke A; Lippert G; Klostermann W; Mayer G; Augspach-Hofmann R; Fitzek S; Haensch CA; Reuland M; Koenig SA
    Seizure; 2006 Sep; 15(6):443-8. PubMed ID: 16787750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperammonemia following intravenous valproate loading.
    DeWolfe JL; Knowlton RC; Beasley MT; Cofield S; Faught E; Limdi NA
    Epilepsy Res; 2009 Jul; 85(1):65-71. PubMed ID: 19299111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gait instability in valproate-treated patients: Call to measure ammonia levels.
    Kipervasser S; Elger CE; Korczyn AD; Nass RD; Quesada CM; Neufeld MY
    Acta Neurol Scand; 2017 Nov; 136(5):401-406. PubMed ID: 28436001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secondary hyperammonaemia: a possible mechanism for valproate encephalopathy.
    Coulter DL; Allen RJ
    Lancet; 1980 Jun; 1(8181):1310-1. PubMed ID: 6104123
    [No Abstract]   [Full Text] [Related]  

  • 26. [The decreased level of plasma carnitine in patients with epilepsy].
    Belousova ED
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):106-110. PubMed ID: 28745680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both?
    Latour P; Biraben A; Polard E; Bentué-Ferrer D; Beauplet A; Tribut O; Allain H
    Hum Psychopharmacol; 2004 Apr; 19(3):193-203. PubMed ID: 15079854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
    Yamada H; Shishido T; Mukai T; Araki M; Naka H; Tokinobu H
    Rinsho Shinkeigaku; 2019 May; 59(5):258-263. PubMed ID: 31061301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired fatty acid oxidation in children on valproic acid and the effect of L-carnitine.
    Kossak BD; Schmidt-Sommerfeld E; Schoeller DA; Rinaldo P; Penn D; Tonsgard JH
    Neurology; 1993 Nov; 43(11):2362-8. PubMed ID: 8232957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hyperammonemic encephalopathy associated with valproate acid].
    Osuna MT; Burcet J; Ramió L; Ustrell X; Silva Y; Molins A
    Neurologia; 2003; 18(6):347-50. PubMed ID: 12838456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valproate-induced encephalopathy.
    Chen WT; Yen DJ; Yu HY; Liao KK
    Zhonghua Yi Xue Za Zhi (Taipei); 2001 Aug; 64(8):474-8. PubMed ID: 11720147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease).
    Larsen EP; Ostergaard JR
    Seizure; 2014 Jun; 23(6):429-34. PubMed ID: 24647346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short chain fatty acids in plasma and brain: quantitative determination by gas chromatography.
    Bachmann C; Colombo JP; Berüter J
    Clin Chim Acta; 1979 Mar; 92(2):153-9. PubMed ID: 487569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia.
    Yagi M; Nakamura T; Okizuka Y; Oyazato Y; Kawasaki Y; Tsuneishi S; Sakaeda T; Matsuo M; Okumura K; Okamura N
    Pediatr Int; 2010 Oct; 52(5):744-8. PubMed ID: 20456087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.
    Yamamoto Y; Takahashi Y; Suzuki E; Mishima N; Inoue K; Itoh K; Kagawa Y; Inoue Y
    Epilepsy Res; 2012 Sep; 101(3):202-9. PubMed ID: 22542569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation.
    Schiavo A; Maldonado C; Vázquez M; Fagiolino P; Trocóniz IF; Ibarra M
    Eur J Pharm Sci; 2023 Apr; 183():106399. PubMed ID: 36740101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Role of hyperammonemia in stuporous states induced by sodium valproate].
    Warter JM; Marescaux C; Rumbach L; Micheletti G; Chabrier G; Koehl C; Imler M; Collard M
    Rev Neurol (Paris); 1983; 139(12):753-7. PubMed ID: 6420866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of valproate and citrulline on ammonium-induced encephalopathy.
    Stephens JR; Levy RH
    Epilepsia; 1994; 35(1):164-71. PubMed ID: 8112241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
    Zhu X; Li X; Zhang T; Zhao L
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):628-634. PubMed ID: 29791065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of relationship between sodium valproate-induced adverse effects and the plasma concentration of its metabolite 2-propylpenten-4-oic acid.
    Paganini M; Zaccara G; Moroni F; Campostrini R; Bendoni L; Arnetoli G; Zappoli R
    Eur J Clin Pharmacol; 1987; 32(2):219-22. PubMed ID: 3108013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.